4-aminopyridine Treatment for Nerve Injury

To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.

Trial Details

NCT ID
NCT03701581
Phase
PHASE2 / PHASE3
Sponsor
John Elfar
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • 4-Aminopyridine
  • Placebo
Locations (sample)
  • Tucson, Arizona, United States|32.22174,-110.92648
  • Rochester, New York, United States|43.15478,-77.61556

Key Eligibility Criteria

  • Male patients with organ-confined, non-metastatic prostate cancer (stages cT1c-T2c), planning to undergo Robotic-Assisted Laparoscopic Bilateral Ne…
  • Prostate-Specific Antigen (PSA) levels less than 15 ng/ml (within the last 12 months), with biopsy-proven prostate cancer, for whom postoperative a…
  • Ages 45-75
  • An Abridged International Index of Erectile Function-Erectile Function (IIEF-5) score of greater than or equal to 17 at time of screening

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →